Drug Boosts Mobility, Extends Lifespan in Mice
- MADRID — an experimental drug, MP-010, has demonstrated the potential to improve motor function and extend life expectancy in mouse models of amyotrophic lateral sclerosis (ALS), according to...
- The study, published in the British Journal of Pharmacology, investigated the modulation of ryanodine receptors (RyRs), proteins crucial for regulating calcium levels within neurons.
- Researchers found that MP-010 stabilized RyR function in ALS mouse models.
experimental Drug Shows Promise in ALS Mouse Models
Table of Contents
- experimental Drug Shows Promise in ALS Mouse Models
- Experimental Drug MP-010: Promising Results in ALS Mouse Models – Your Questions Answered
- What is Amyotrophic Lateral Sclerosis (ALS)?
- What is MP-010?
- How does MP-010 work?
- What results were seen in the ALS mouse models?
- Who lead the research on MP-010?
- Where was this research published?
- What are the next steps for MP-010?
- What is the role of Miramoon pharma in the growth of MP-010?
- What is the importance of RyRs in ALS?
- What is the Importance of Collaboration in this Research?
- Key Findings: Summary of MP-010’s Effects
MADRID — an experimental drug, MP-010, has demonstrated the potential to improve motor function and extend life expectancy in mouse models of amyotrophic lateral sclerosis (ALS), according to research led by the Network biomedical Research Center (CIBERNED).
The study, published in the British Journal of Pharmacology, investigated the modulation of ryanodine receptors (RyRs), proteins crucial for regulating calcium levels within neurons. Dysregulation of calcium is a key factor in the progression of ALS, a neurodegenerative disease affecting approximately 4,000 people in Spain.
Researchers found that MP-010 stabilized RyR function in ALS mouse models. The effectiveness of the drug was assessed through nerve and muscle function tests, histological analysis, and survival rate monitoring.
The results showed that MP-010 preserved nerve function, delayed the appearance of motor problems, improved muscle coordination, maintained the neuromuscular connections and protected the motor neurons in the spinal cord.
laura Moreno-Martínez, Cyberned researcher at the University of Zaragoza and the Biomedical Research Center of Aragon (CIBA)
Mice treated with MP-010 lived longer than those receiving a placebo, according to the study. The researchers suggest that drugs targeting RyRs could hold therapeutic potential for treating ALS. However, they cautioned that further research is needed to fully understand the drugS molecular mechanisms and assess its viability in humans.
The research was led by Adolfo López de Munain, from the University of the Basque Country and IIS Biogipuzkoa; Francisco Gil-Bea, of Ikerbasque, University of Navarra and IIS Biogipuzkoa; rosario Osta, from the University of Zaragoza and Iis Aragón; and Xavier Navarro, from the Autonomous University of Barcelona. López de Munain and Gil-Bea are co-founders of Miramoon pharma,the company that developed MP-010.
CIBERNED emphasized the importance of multidisciplinary collaboration in the success of the research. The research team noted that Miramoon Pharma’s involvement was crucial not only in the development of MP-010 but also in accelerating the drug discovery process, highlighting the value of partnerships with innovative startups to advance new therapies.
Experimental Drug MP-010: Promising Results in ALS Mouse Models – Your Questions Answered
What is Amyotrophic Lateral Sclerosis (ALS)?
ALS, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. This leads to the loss of muscle control, causing weakness, and eventually, paralysis. The article mentions that approximately 4,000 people in Spain are affected by ALS.
What is MP-010?
MP-010 is an experimental drug being developed to treat ALS. According to the research, MP-010 has shown promising results by potentially improving motor function and extending life expectancy in mouse models of ALS.
How does MP-010 work?
The research focused on ryanodine receptors (RyRs), proteins that regulate calcium levels within neurons. Dysregulation of calcium is a meaningful factor in ALS progression.MP-010 works by stabilizing RyR function, potentially mitigating the harmful effects of calcium dysregulation in the affected neurons. This stabilization helps protect motor neurons and preserve thier function.
What results were seen in the ALS mouse models?
The study showed several positive effects of MP-010, including:
- Preserved nerve function
- Delayed the appearance of motor problems
- Improved muscle coordination
- Maintained neuromuscular connections
- Protected motor neurons in the spinal cord
- Extended lifespan compared to a placebo group
Who lead the research on MP-010?
The research was led by a team of researchers from several institutions:
- Adolfo López de munain (University of the basque Country and IIS Biogipuzkoa)
- Francisco Gil-Bea (Ikerbasque, University of Navarra and IIS Biogipuzkoa)
- Rosario Osta (University of Zaragoza and Iis Aragón)
- Xavier Navarro (Autonomous university of Barcelona)
Where was this research published?
The research findings were published in the British Journal of Pharmacology.
What are the next steps for MP-010?
The study’s authors emphasize that further research is needed to fully understand MP-010’s molecular mechanisms and assess its viability in humans. This next phase may involve further preclinical studies and clinical trials.
What is the role of Miramoon pharma in the growth of MP-010?
Adolfo López de Munain and Francisco Gil-Bea, the lead researchers on this project, are co-founders of Miramoon Pharma, the company that developed MP-010. Miramoon Pharma’s involvement was crucial, not only in developing the drug, but also in speeding up the drug revelation process.
What is the importance of RyRs in ALS?
ryanodine receptors (RyRs) are proteins essential for regulating calcium levels inside neurons. In ALS,calcium dysregulation is a key factor in disease progression,contributing to neuronal damage. MP-010’s potential lies in its ability to stabilize RyR function, addressing this critical aspect of the disease.
What is the Importance of Collaboration in this Research?
CIBERNED emphasized the importance of multidisciplinary collaboration in the research’s success. The research team noted that partnerships with innovative startups like Miramoon Pharma were crucial, highlighting their value in pushing forward new therapies.
Key Findings: Summary of MP-010’s Effects
Here’s a brief overview of the positive effects of MP-010 observed in this study:
| Effect | Description |
|---|---|
| Motor Function | Improved motor function and muscle coordination |
| Nerve Function | preserved nerve function |
| Motor Neuron Protection | Helped protect motor neurons in the spinal cord |
| Neuromuscular Connections | Maintained neuromuscular connections |
| Lifespan | Extended the lifespan of mice with ALS compared to placebo |